jili jili777 India News | 3 Dead, 9 Injured in Road Accident in Karnataka's Kalaburagi80% to China, 7% to India, Brazil. Renewable energy investment imbalance needs to fixed: Ajay Mathur, International Solar Alliance

PORTLAND, Ore. (AP) — Googly eyes have been appearing on sculptures around the central Oregon city of Bend, delighting many residents and sparking a viral sensation covered widely by news outlets and featured on a popular late-night talk show. On social media, the city shared photos of googly eyes on installations in the middle of roundabouts that make up its so-called “Roundabout Art Route.” One photo shows googly eyes placed on a sculpture of two deer, while another shows them attached to a sphere. It's not yet known who has been putting them on the sculptures. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

2024's Most Read Science Stories

Annaly Capital Management, Inc. ( NYSE:NLY – Get Free Report ) announced a quarterly dividend on Thursday, December 5th, RTT News reports. Investors of record on Tuesday, December 31st will be given a dividend of 0.65 per share by the real estate investment trust on Friday, January 31st. This represents a $2.60 annualized dividend and a yield of 13.73%. The ex-dividend date of this dividend is Tuesday, December 31st. Annaly Capital Management has decreased its dividend by an average of 2.0% annually over the last three years. Annaly Capital Management has a payout ratio of 94.5% indicating that its dividend is currently covered by earnings, but may not be in the future if the company’s earnings fall. Analysts expect Annaly Capital Management to earn $2.65 per share next year, which means the company should continue to be able to cover its $2.60 annual dividend with an expected future payout ratio of 98.1%. Annaly Capital Management Stock Down 0.2 % NYSE:NLY opened at $18.94 on Friday. The stock has a market cap of $10.62 billion, a P/E ratio of -270.57 and a beta of 1.51. The business’s 50-day moving average price is $19.51 and its two-hundred day moving average price is $19.81. Annaly Capital Management has a twelve month low of $17.67 and a twelve month high of $21.11. Wall Street Analyst Weigh In A number of research analysts recently commented on the company. Argus raised Annaly Capital Management from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Thursday, October 31st. JPMorgan Chase & Co. reduced their price objective on Annaly Capital Management from $21.00 to $20.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. Finally, Wells Fargo & Company upgraded Annaly Capital Management from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $19.00 to $23.00 in a research report on Friday, September 20th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Annaly Capital Management currently has a consensus rating of “Moderate Buy” and an average target price of $21.50. Check Out Our Latest Report on Annaly Capital Management About Annaly Capital Management ( Get Free Report ) Annaly Capital Management, Inc, a diversified capital manager, engages in mortgage finance. The company invests in agency mortgage-backed securities collateralized by residential mortgages; non-agency residential whole loans and securitized products within the residential and commercial markets; mortgage servicing rights; agency commercial mortgage-backed securities; to-be-announced forward contracts; residential mortgage loans; and agency or private label credit risk transfer securities. See Also Receive News & Ratings for Annaly Capital Management Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annaly Capital Management and related companies with MarketBeat.com's FREE daily email newsletter .

RESTON, Va., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC ) announced today that the company's board of directors declared a cash dividend of $0.37 per share of the company's common stock payable on January 24, 2025 to stockholders of record on January 10, 2025. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the board of directors each quarter and will depend on earnings, financial condition, capital requirements and other factors. About SAIC SAIC is a premier Fortune 500® technology integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives. We are approximately 24,000 strong; driven by mission, united by purpose, and inspired by opportunities. SAIC is an Equal Opportunity Employer, fostering a culture of diversity, equity and inclusion, which is core to our values and important to attract and retain exceptional talent. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.4 billion.​​​​ For more information, visit saic.com . For ongoing news, please visit our newsroom . Forward-Looking Statements Certain statements in this release contain or are based on "forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects,” "intends,” "plans,” "anticipates,” "believes,” "estimates,” "guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the "Risk Factors,” "Management's Discussion and Analysis of Financial Condition and Results of Operations” and "Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC's website at sec.gov . Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC's expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others. Media Contact: Kara Ross [email protected]

MoU signed between Water Resources Department and SAC-ISRO under leadership of Gujarat CMCardiac Resynchronization Therapy Market to See Rapid Expansion Over the Next Decade 2024-2032 12-25-2024 03:09 PM CET | Health & Medicine Press release from: Cognate Insights Cardiac Resynchronization Therapy Market Latest Market Overview The global cardiac resynchronization therapy (CRT) market is anticipated to reach $6.2 billion by 2024, with a projected compound annual growth rate (CAGR) of 6.1% from 2024 to 2032. Rising cases of chronic heart failure and advanced cardiac disorders have escalated the demand for CRT devices. With increased focus on improving patient outcomes in heart failure cases, the market for CRT devices is gaining momentum, especially in regions with higher aging populations. The report emphasizes growth opportunities driven by the adoption of technologically advanced CRT-P and CRT-D devices. The Cardiac Resynchronization Therapy Market has experienced steady growth in recent years and is expected to continue expanding at a strong pace from 2024 to 2032. This analysis offers a comprehensive overview, providing valuable insights into key trends and developments within the Cardiac Resynchronization Therapy industry. These findings equip business leaders with the necessary knowledge to devise more effective strategies and enhance profitability. Furthermore, the report serves as a useful resource for new and emerging businesses, helping them make informed decisions as they navigate the market and seek growth opportunities. Major Players of Cardiac Resynchronization Therapy Market are: Medtronic PLC, Ireland - $31.5 billion revenue Boston Scientific Corporation, USA - $11.9 billion revenue Abbott Laboratories, USA - $43.6 billion revenue Biotronik SE & Co. KG, Germany - $1.1 billion revenue Koninklijke Philips N.V., Netherlands - $20.3 billion revenue Get Latest PDF Sample Report @ https://www.cognateinsights.com/request-sample/cardiac-resynchronization-therapy-market Our Report covers global as well as regional markets and provides an in-depth analysis of the overall growth prospects of the market. Global market trend analysis including historical data, estimates to 2024, and compound annual growth rate (CAGR) forecast to 2032 is given based on qualitative and quantitative analysis of the market segments involving economic and non-economic factors. Furthermore, it reveals the comprehensive competitive landscape of the global market, the current and future market prospects of the industry, and the growth opportunities and drivers as well as challenges and constraints in emerging and emerging markets. Global Cardiac Resynchronization Therapy Market Landscape and Future Pathways: North America: United States Canada Europe: Germany France U.K. Italy Russia Asia-Pacific: China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America: Mexico Brazil Argentina Korea Colombia Middle East & Africa: Turkey Saudi Arabia UAE Korea Speak to Our Analyst for A Discussion on The Above Findings, And Ask for A Discount on The Report @ https://www.cognateinsights.com/check-discount/cardiac-resynchronization-therapy-market Key drivers and challenges influencing the Cardiac Resynchronization Therapy market: Regional Analysis: The report involves examining the Cardiac Resynchronization Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets. Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cardiac Resynchronization Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends. Company Analysis: Report covers individual Cardiac Resynchronization Therapy manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies. Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cardiac Resynchronization Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application. Technology Analysis: Report covers specific technologies relevant to Cardiac Resynchronization Therapy. It assesses the current state, advancements, and potential future developments in Cardiac Resynchronization Therapy areas. Reason to Buy this Report: -Analysis of the impact of technological advancements on the market and the emerging trends shaping the industry in the coming years. -Examination of the regulatory and policy changes affecting the market and the implications of these changes for market participants. -Overview of the competitive landscape in the Cardiac Resynchronization Therapy market, including profiles of the key players, their market share, and strategies for growth. -Identification of the major challenges facing the market, such as supply chain disruptions, environmental concerns, and changing consumer preferences, and analysis of how these challenges will affect market growth. -Evaluation of the potential of new products and applications in the market, and analysis of the investment opportunities for market participants. For In-Depth Competitive Analysis - Purchase this Report now at @ https://www.cognateinsights.com/purchase-report/cardiac-resynchronization-therapy-market Contact Us: Cognate Insights Web: www.cognateinsights.com Email: info@cognateinsights.com Phone: +91 8424946476 About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.